RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for ...
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today ...
Science 37 has been tapped to use its virtual clinical trial tech for phase 3 trials of Synlogic’s treatment for the rare genetic metabolic disorder phenylketonuria (PKU). Under the deal, Science 37’s ...
PLAYA VISTA, Calif.--(BUSINESS WIRE)--Science 37, a trailblazing company focused on “site-less” clinical trials, announced today the completion of a Phase 2b study for AOBiome, a clinical-stage life ...
Science 37 was recognized for the Participant Engagement Award for its "Pharm-to-Trial" partnership with RxE2. This decentralized vaccine trial model brings research to agricultural U.S. communities ...
MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease ...
MORRISVILLE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, today announced that it has been awarded the Research and Development – Site ...
Remote clinical trial company Science 37 has raised $29 million in a round led by Glynn Capital Management with participation from Google's investment arm GV. One more new investor -- AmGen ventures - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback